Tag: Herceptin

Articles

• HER2/neu overexpressing breast cancer
• How can young breast cancer survivors avoid a recurrence?
• How to optimize your breast cancer diet
• Latest research concerning HER2 positive breast cancer prognosis
• What should breast cancer patients and survivors eat during Herceptin treatment?
• What should HER2/neu breast cancer patients and survivors eat?

News

• BMI, type 2 diabetes, and breast cancer prognosis
• Breast cancer type and survival statistics 1999-2004
• ER negative, PR negative, and triple negative tumors have increased risk of locoregional recurrence
• Erythropoietin for anemia may hinder Herceptin treatment for HER2-positive breast cancer
• Flaxseed enhances Herceptin treatment in mouse model of HER2 breast cancer
• Herceptin has reduced locoregional recurrence for HER2+ compared to triple negative breast cancer
• Herceptin increases survival time for Stage IV HER2 breast cancer patients
• Herceptin plus anthracycline chemotherapy greatly increases risk of heart damage
• Metformin improves survival of diabetic women with HER2+ breast cancer
• Non-anthracycline chemotherapy plus Herceptin is effective treatment for HER2+ breast cancer
• Possible toxic side effects of chemotherapy
• Response to neoadjuvant chemotherapy depends on dosage and tumor type
• Survival times for metastatic breast cancer have been improving
• Treatment with Herceptin for one year improves survival in women with HER2+ breast cancer

Foods

• flaxseed  green tea  macadamia nuts 

Studies

• Addition of Bevacizumab to Conventional Therapy Improved Progression-Free Survival in HER2-Positive Breast Cancer
• Addition of Trastuzumab May Potentially Equalize Disease-Free Survival Outcomes Among Obese and Normal-Weight Patients
• Additive effects of trastuzumab and genistein on human breast cancer cells
• Adjuvant Trastuzumab in HER2-Positive Breast Cancer
• Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer
• Cardiotoxic Chemotherapy is Associated with Increased Heart Failure Risk Among Women with Breast Cancer in the Cancer Research Network
• Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
• Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy
• Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3
• Early identification of trastuzumab-related cardiotoxicity with speckle-tracking echocardiography
• Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
• Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network
• Fifteen-year trends in metastatic breast cancer survival in Greece
• Flaxseed oil-trastuzumab interaction in breast cancer
• HER 2 ( erb B-2)-targeted effects of the ϖ-3 polyunsaturated. Fatty acid α-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the fat features of the Mediterranean diet as an anti-HER2 cocktail
• Impact of BMI on clinical outcome of HER2-positive breast cancer
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
• Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells
• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib
• Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification
• Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
• Outcomes of inflammatory versus noninflammatory T4 breast cancers in the age of taxanes and trastuzumab
• Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
• Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
• Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation
• Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer: Results from the GeparQuattro study (GBG 40)
• Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation
• The effect of trastuzumab alone and combined with α-linolenic acid, γ-tocopherol, sesame lignan and its metabolites on the growth of BT-474 and MCF-7 human breast cancer cells
• Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
• Trastuzumab-Resistant HER2-Driven Breast Cancer Cells Are Sensitive to Epigallocatechin-3 Gallate
• Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial